AstraZeneca reported positive Phase III results for tozorakimab in COPD, meeting the primary endpoint with clinically ...

Add Yahoo as a preferred source to see more of our stories on Google. May 11—(StatePoint) IgA nephropathy is a progressive, autoimmune, chronic disease that predominantly affects adults between the ...

April 21 (Reuters) - AstraZeneca said on Tuesday its rare blood disorder drug Ultomiris has met the main goal of a late-stage ...

IgA nephropathy (IgAN) is a kidney disorder caused by a buildup of immune complexes and the antibody called immunoglobulin A (IgA) inside the kidneys. This buildup causes inflammation in the kidneys.

Adults with IgA nephropathy treated with ravulizumab show significant proteinuria improvement as early as week 10.

IgA nephropathy, also known as Berger’s disease, is a progressive, autoimmune, chronic kidney disease that predominantly affects adults between the ages of 20 and 40. It is characterized by the ...

Andrew S. Bomback, MD, MPH, comments on the impact of disparities in diagnosing and treating IgA nephropathy by nephrologists. Early detection and treatment of IgA nephropathy are critical for better ...

A high rate of serious adverse events led to the premature termination of a clinical trial designed to evaluate the efficacy of oral methylprednisolone in patients with immunoglobulin A (IgA) ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We don't know what causes a patient to ...

Between 20 and 50 percent of individuals with IgA nephropathy will experience kidney failure within two decades of diagnosis, though the timeline varies significantly from person to person. Regular ...

Patients with IgA nephropathy, extensive crescentic disease (more than 50% glomerular involvement), and a rapidly progressive course (monthly decline in eGFR of more than 25-30 mL/min/1.73m 2) are ...